FT522: A CAR NK Cell with the Unique Ability to Target Multiple Pathogenic Cell Types and Circumvent Lympho-conditioning in Systemic Autoimmunity
Wednesday, May 8, 2024 1 min read
Key Takeaway: The article discusses FT522, a CAR NK cell designed to target multiple pathogenic cell types and avoid lympho-conditioning in systemic autoimmunity. However, it provides minimal details on the cell's performance or clinical implications. The content primarily focuses on website privacy and cookie usage rather than the biopharma topic.
Price reaction · baseline $3.725 (2024-05-08T15:33:00.000Z) · hit during market hours · 2 other FATE headline(s) in the window, move may be shared
day 0 close · peak
-0.7%
Market Sentiment Analysis
CONCERNS & RISKS
The article lacks substantial information regarding FT522.
No specific details about the CAR NK cell's efficacy or trials are provided.
Full Press Release Details
• Privacy Overview
• Strictly Necessary Cookies
• 3rd Party Cookies
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
For more information about the data we collect please visit our Privacy Policy .
Strictly Necessary Cookies is enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.